Head-To-Head Analysis: MediWound (NASDAQ:MDWD) & Dyne Therapeutics (NASDAQ:DYN)

Dyne Therapeutics (NASDAQ:DYN) and MediWound (NASDAQ:MDWD) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, profitability, dividends, valuation, institutional ownership and earnings.

Profitability

This table compares Dyne Therapeutics and MediWound’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Dyne Therapeutics	N/A	-61.46%	-50.94%
MediWound	-140.80%	-65.79%	-30.16%

Analyst Recommendations

This is a summary of recent recommendations and price targets for Dyne Therapeutics and MediWound, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dyne Therapeutics	1	2	11	3	2.94
MediWound	1	1	3	0	2.40

Dyne Therapeutics presently has a consensus target price of $35.14, indicating a potential upside of 86.53%. MediWound has a consensus target price of $31.67, indicating a potential upside of 88.38%. Given MediWound’s higher probable upside, analysts clearly believe MediWound is more favorable than Dyne Therapeutics.

Insider and Institutional Ownership

96.7% of Dyne Therapeutics shares are held by institutional investors. Comparatively, 46.8% of MediWound shares are held by institutional investors. 14.1% of Dyne Therapeutics shares are held by company insiders. Comparatively, 9.2% of MediWound shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Valuation and Earnings

This table compares Dyne Therapeutics and MediWound”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dyne Therapeutics	N/A	N/A	-$446.21 million	($3.54)	-5.32
MediWound	$16.96 million	12.74	-$23.88 million	($2.10)	-8.00

MediWound has higher revenue and earnings than Dyne Therapeutics. MediWound is trading at a lower price-to-earnings ratio than Dyne Therapeutics, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Dyne Therapeutics has a beta of 1.29, indicating that its share price is 29% more volatile than the S&P 500. Comparatively, MediWound has a beta of 0.15, indicating that its share price is 85% less volatile than the S&P 500.

Summary

Dyne Therapeutics beats MediWound on 9 of the 14 factors compared between the two stocks.

About Dyne Therapeutics

Dyne Therapeutics, Inc., a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.

About MediWound

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; and MW005, which is in phase I/II for the treatment of low-risk basal cell carcinoma. MediWound Ltd. was incorporated in 2000 and is headquartered in Yavne, Israel.